The Battle Against Hormone-Refractory Prostate Cancer

Is Satraplatin the Second-Line Savior?
Emerging Technologies

Executive summary

Approximately 234 000 American men will be diagnosed with prostate cancer in 2006 and many will require treatment. One of the major medical needs for this patient group is a therapeutic option for hormone-refractory prostate cancer (HRPC) when standard care with Taxotere® (docetaxel) is ineffective.

The main hope for second-line therapy of HRPC is satraplatin, a novel oral platinum drug in development with the German company GPC Biotech. Satraplatin is currently being investigated for second-line therapy of HRPC in a pivotal phase III trial, and GPC Biotech began filing for US FDA approval of the drug in December 2005 by way of a rolling New Drug Application. An independent data monitoring board recommended in April that the trial should continue through to completion. Efficacy data are anticipated to become available in Q3 of 2006 and, assuming positive results, the FDA filing may be completed by year-end — suggesting that satraplatin could be on the market within a...


Prostate Cancer Docetaxel Estramustine Taxotere Pivotal Phase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society. Cancer Facts and Figures 2006. Atlanta (GA): American Cancer Society, 2006Google Scholar
  2. 2.
    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502–12PubMedCrossRefGoogle Scholar
  3. 3.
    Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513–20PubMedCrossRefGoogle Scholar
  4. 4.
    Sternberg CN, Whelan P, Hetherington JL, et al. Phase III trial of satraplatin, an oral platinum, plus prednisone vs prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68: 2–9PubMedCrossRefGoogle Scholar
  5. 5.
    GPC Biotech. Interim analysis news neither necessarily positive or negative. New York: Lehman Brothers Global Equity Research, 2006Google Scholar
  6. 6.
    Trials and tribulations in prostate cancer: Xinlay rejected by US FDA committee. Pharm Diagn Innov 2005; 3 (10): 11–3Google Scholar
  7. 7.
    GPC Biotech. Operating results — FY 2005 results. New York: Lehman Brothers Global Equity Research, 2006Google Scholar
  8. 8.
    GPC Biotech. Change of price target. New York: Lehman Brothers Global Equity Research, 2006Google Scholar

Copyright information

© Adis Data Information BV 2006

Personalised recommendations